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Abstract 1 
The structure-activity relationship of new 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as 2 
adenosine receptors (ARs) antagonists has been explored. The introduction of a benzylamino group 3 
at C5 with a free amino group at C7 increases the affinity toward all the ARs subtypes (10: KihA1 = 4 
94.6 nM; KihA2A = 1.11 nM; IC50hA2B = 2,214 nM; KihA3 = 30.8 nM). Replacing the free amino 5 
group at C7 with a phenylureido moiety yields a potent and quite selective hA2A AR antagonist (14: 6 
hA2A AR Ki = 1.44 nM; hA1/hA2A = 216.0; hA3/hA2A = 20.6). This trend diverges from the analysis 7 
on the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine series previously reported. With the help of 8 
an in silico receptor-driven approach, we have rationalized these observations and elucidated from a 9 
molecular point of view the role of the benzylamino group at C5 in determining affinity toward the 10 
hA2A AR. 11 
 12 
Keywords. G protein-coupled receptor; antagonists; molecular modelling; structure activity 13 
relationship; triazolo-triazine; adenosine receptors. 14 
Abbreviations. AR, adenosine receptor; CCPA, 2-chloro-N6-cyclopentyladenosine; CHO, Chinese 15 
hamster ovary; IEele, per residue electrostatic contributions to the interaction energy; IEFs, 16 
Interaction Energy Fingerprints; IEhyd, per residue hydrophobic contributions to the interaction 17 
energy; NECA, 5’-N-ethylcarboxamidoadenosine; PTP, pyrazolo[4,3-e][1,2,4]triazolo[1,5-18 
c]pyrimidine;  R-PIA, R-(-)-N6-(2-phenylpropyl)adenosine; TEA, triethylamine; ZM241385, 4-[2-19 
[7-amino-2-(2-furyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethylphenol; TM, 20 
transmembrane; TT, [1,2,4]triazolo[1,5-a][1,3,5]triazine; EL2, second extracellular loop. 21 
22 
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1. Introduction 1 
 2 
Adenosine receptors (ARs) are members of the G protein-coupled receptors (GPCRs) superfamily. 3 
To date, four ARs subtypes - the A1 AR, A2A AR, A2B AR, and A3 AR - are currently known1, that 4 
exert their physiological functions through the activation or inhibition of various second messenger 5 
systems. In particular, the modulation of adenylate cyclase activity is considered the principal 6 
intracellular signal transduction mediated by these receptors2,3. Activation or blockade of ARs is 7 
responsible for a wide range of effects in numerous organ systems suggesting potential therapeutic 8 
applications of ARs modulators. In particular, the cardioprotective4,5 and neuroprotective6,7 effects 9 
associated with ARs activation have been clearly demonstrated during periods of cardiac and 10 
cerebral ischemia, respectively. Moreover, the use of antagonists of distinct AR subtypes could be 11 
useful in the treatment of asthma8,9 or neurological diseases such as Parkinson’s disease10.  12 
In recent years, the synthesis of a large variety of ARs agonists and antagonists for the 13 
pharmacological characterization of this GPCRs family has been reported11. Diverse classes of 14 
heterocyclic derivatives have been proposed as ARs antagonists, exhibiting high levels of both 15 
affinity and selectivity. Within this framework, our research groups have extensively investigated 16 
the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (PTP) nucleus as basis for the design of ARs 17 
antagonists12-23. Through the modulation of the substitution pattern at the C5 (C5PTP) and N7 (N7PTP) 18 
positions, potent and selective human (h) A2A AR and A3 AR antagonists (compounds A15 and B18, 19 
Chart 1) were reported. Nevertheless, these derivatives, likewise to other tricyclic structures, suffer 20 
from limited aqueous solubility and require complicated synthetic routes. To overcome these 21 
limitations, we explored in recent years the synthesis of simplified bicyclic systems, such as 22 
[1,2,4]triazolo[1,5-c]pyrimidines24, and [1,2,4]triazolo[1,5-a][1,3,5]triazines (TT)25,22. The TT 23 
nucleus, in particular, represents one of the most appealing bicyclic cores. In fact, one of the most 24 
potent and selective A2A AR antagonists yet reported − 4-[2-[7-amino-2-(2-furyl)-25 
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethylphenol (ZM241385, Chart 2) − is based on this 26 
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scaffold26,27. This compound also binds with good affinity to the hA2B AR (28 nM), and its tritiated 1 
form is used as radioligand for this receptor subtype28. 2 
 3 
Chart 1. Previously reported pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine as hARs antagonists. 4 
 5 
Chart 2. Structure of ZM 241385. 6 
In recent years22, we explored the structure-activity-relationship (SAR) of the introduction at C5 7 
position of the TT scaffold of solubilizing groups aimed at enhancing both the aqueous solubility 8 
and the physicochemical properties. The resulting compounds maintained potency at the hA2A AR 9 
and, in some cases, subtype selectivity. In another study25, we investigated the effect of the 10 
substitutions at both the C5 and C7 position: compounds bearing a free amino group in C7 showed 11 
good affinity at the rat (r) A2A AR, whereas the introduction of a phenylureido moiety slightly 12 
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increased the affinity at the hA3 AR with respect to the unsubstituted derivatives. In the present 1 
study, we further explore both the C5 and C7 positions. The newly synthesized compounds have 2 
been assessed at all four hARs, and the results rationalized from a molecular point of view with the 3 
help of computational methodologies. 4 
2. Results and Discussion 5 
2.1 Chemistry 6 
All the compounds were synthesized according to the procedure reported in Schemes 1-3.  5,7-7 
Diphenoxy-2-furoyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine (5) and  7-amino-5-phenoxy-2-furoyl-8 
[1,2,4]triazolo[1,5-a][1,3,5]triazine (6) were obtained following the procedure reported in literature 9 
by Caulkett et al. as depicted in Scheme 129.  10 
 11 
Scheme 1. Reagents: (i) PhOH, rfx, 5h; (ii) a. NH2NH2.H2O, DCM, rt, 12h; b. iPrOH, rt, 14h; (iii) 12 
2-furoylchloride, TEA, DCM, rt, 15h; (iv) P2O5, xylene, rfx, 14h; (v) NH3/MeOH, rfx, 4h. 13 
By reacting compound 6 with the appropriate amines in ethanol, in a sealed tube at 100 °C, the 7-14 
amino-5-aminosubstituted-2-furoyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives (7-10) were 15 
obtained. Compounds 8-10 were already reported by Caulkett & coll30. Reaction of derivatives 7-10 16 
with phenylisocyanate gives the corresponding 7-phenylureas (11-14) while reaction with benzoyl 17 
chloride or phenylacetyl chloride affords the corresponding 7-amido derivatives (15-22, Scheme 2). 18 
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 1 
Scheme 2. Reagents: (i) NH2R, EtOH, 100 °C, 3-72h; (ii) PhNCO, dioxane, rfx, 24h; (iii) R'COCl, 2 
TEA, dioxane, rfx, 24h. 3 
The synthetic pathway to obtain the 5,7-diaminosubstituted compounds (26-37) is reported in 4 
Scheme 3. Firstly, the 5,7-diphenoxy-2-furoyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine (5) was 5 
substituted at the C5 position with different amines in ethanol, in a sealed tube at 60°C (23-25). 6 
Then, the treatment of the obtained derivatives (23-25) with a second appropriate amine in ethanol, 7 
in a sealed tube at 70-100 °C, yielded the desired 5,7-diaminosubstituted TT derivatives (26,27,29-8 
32,34-36). Compounds substituted with the same amino group both at the C5 and C7 positions 9 
(28,33,37) were obtained by reaction between compound 5 and the desired amine at higher 10 
temperature (90-120°C) or using amine in larger excess (5 eq).  11 
 12 
Scheme 3. Reagents: (i) NH2R, EtOH, 60-120 °C, 3-24h; (ii) NH2R', EtOH, 70-100 °C, 24-72h. 13 
 14 
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2.2 Biological Activity 1 
The synthesized compounds (7-37) were tested at the human (h) A1, A2A and A3 ARs expressed in 2 
CHO cells: [3H]CCPA (A1), [3H]NECA (A2A) and [3H]HEMADO (A3) were used as radioligands in 3 
binding assays3, whereas the activity at the hA2B AR was determined through the measurement of 4 
the inhibition of NECA-stimulated adenylyl cyclase activity. The receptor binding affinities of the 5 
synthesized compounds (7-37) are reported in Table 1. The derivatives can be divided into seven 6 
subseries according to the substituent at the C7 position as compounds bearing: (a) a free amino (7-7 
10); (b) a phenylureido (11-14); (c) a benzamido (15-18); (d) a phenylacetamido (19-22); (e) a 8 
cyclohexylamino (23, 26-29); (f) a benzylamino (24, 30-33); or (g) a 4-fluoro-benzylamino (25, 34-9 
37) group. 10 
All the derivatives display poor affinity toward the hA1 AR. The most potent compounds toward 11 
hA1 AR (9, 10, 29) possess a Ki in the range 63.9-138 nM (i.e. 9: KihA1 = 138 nM; 10: KihA1 = 12 
94.6 nM; 29: KihA1 = 63.9 nM) and belong to the free amino (9, 10) or cyclohexylamino (29) 13 
subseries. However, derivatives 9, 10 and 29 show a better affinity at the hA2A AR than at the hA1 14 
AR (9: KihA2A = 3.56 nM; 10: KihA2A = 1.11 nM; 29: KihA2A = 15.2 nM). In all the seven subseries, 15 
a common trend can be observed regarding affinity at the hA1 AR: the derivative bearing a 16 
benzylamino moiety at the C5 position exhibits higher affinity with respect to the corresponding 17 
alkylamino compounds (e.g. 18: KihA1 = 1,450 nM vs 15: KihA1 = 10,500 nM; 16: KihA1 = 24,400 18 
nM and 17: KihA1 = 7,560 nM ). 19 
Concerning the hA2B AR, the majority of the newly synthesized derivatives turned out to be inactive 20 
with a IC50 value above 30 µM. The compounds showing IC50 values in the low micromolar range 21 
bear the benzylamino moiety at the C5 position (10: IC50hA2B = 2,214 nM; 14: IC50hA2B = 4,360 22 
nM; 22: IC50hA2B = 7,617 nM; 33: IC50hA2B = 11,800 nM), except for compound 9, which is 23 
substituted with a cyclohexylamino group at the same position (9: IC50hA2B = 1,450 nM).  24 
At the hA2A AR subtype, the most promising compounds belong to the free amino (7-10) and the 25 
phenylureido (11-14) subseries. Interestingly, as also in part observed for the hA1 AR, in all the 26 
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Table 1. Structures and binding profile of synthesized compounds 7-37.  
 
Compd R R’ hA1 
Ki nM 
hA2A 
Ki nM 
hA2B 
IC50 nM 
hA3  
Ki nM 
hA1/hA2A hA3/hA2A 
7 H NHCH3 2,570 
(2,390 - 2,770) 
49.3 
(48.8 - 49.8) 
> 30,000 1,560  
(1,290 - 1,880) 
52.1 31.6 
8 H NHCH(CH3)2 4,310 
(4,220 - 4,410) 
64.8 
(53.3 - 78.7) 
> 30,000 568 
(481 - 671) 
66.5 8.76 
9 H NHcC6H11 138 
(133 - 143) 
3.56 
(2.53 - 5.02) 
13,422 
(8,500 – 21,193) 
370 
(330 - 415) 
38.8 104 
10 H NHCH2Ph 94.6 
(89.6 - 99.9) 
1.11 
(0.83 - 1.48) 
2,214 
(1,209 – 4,053) 
30.8 
(26.8 - 35.5) 
85.2 27.7 
11 CONHPh NHCH3 3,850 
(2,920 - 5,070) 
99.6 
(61.4 - 161) 
> 30,000  572 
(422 - 777) 
38.6 5.74 
12 CONHPh NHCH(CH3)2 1,180 
(1,090 - 1,270) 
86.9 
(54.7 - 138) 
> 30,000 170 
(145 - 199) 
13.6 1.96 
13 CONHPh NHcC6H11 946 
(475 - 1,890) 
7.87 
(4.90 - 12.7) 
> 30,000 349 
(335 - 364) 
120 44.3 
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14 CONHPh NHCH2Ph 311 
(171 - 568) 
1.44 
(1.29 - 1.60) 
4,360 
(1,991 – 9,548) 
29.7 
(24.3 - 36.2) 
216 20.6 
15 COPh NHCH3 10,500 
(8,850 - 12,400) 
194 
(182 - 206) 
 > 30,000  9,240 
(7,410 - 11,500) 
54.1 47.6 
16 COPh NHCH(CH3)2 24,400 
(20,800 - 
28,500) 
2,150 
(2,040 - 2,270) 
 > 30,000 13,400 
(11,900 - 
15,100) 
11.3 6.23 
17 COPh NHcC6H11 7,560 
(6,390 - 8,940) 
1,020 
(828 - 1,250) 
> 30,000 8,500 
(8,170 - 8,840) 
7.41 8.33 
18 COPh NHCH2Ph 1,450 
(1,170 - 1,800) 
95.2 
(75.3 - 120) 
> 30,000 250 
(241 - 258) 
15.2 2.63 
19 COCH2Ph NHCH3 8,960 
(8,460 - 9,500) 
300 
(212 - 424) 
> 30,000 1,670 
(1,400 - 1,980) 
29.9 5.57 
20 COCH2Ph NHCH(CH3)2 7,150 
(6,640 - 7,700) 
 393 
(289 - 533) 
> 30,000 257 
(228 - 290) 
18.2 0.65 
21 COCH2Ph NHcC6H11 1,010 
(933 - 1,090) 
23.6 
(18.3 - 30.5) 
> 30,000 286 
(239 - 341) 
42.8 12.1 
22 COCH2Ph NHCH2Ph 676 
(619 - 737) 
5.39 
(4.32 - 6.73) 
7,617 
(4,080 - 14,223) 
45.5 
(38.6 - 53.7) 
125 8.44 
23 cC6H11 OPh 757  
(575 - 997) 
113 
(85.8 - 148) 
> 30,000 294 
(262 - 329) 
6.70 2.60 
24 CH2Ph OPh > 100,000 560 
(457 - 686) 
> 30,000 375 
(362 - 389) 
> 178 0.67 
25 CH2-4F-Ph OPh > 100,000 905 
(632 - 1,300) 
>  30,000  > 100,000 > 110 > 110 
26 cC6H11 NHCH3 361 
(316 - 412) 
143 
(112 - 182) 
>  30,000 905 
(806 - 1,017) 
2.52 6.33 
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27 cC6H11 NHCH(CH3)2 801 
(723 - 888) 
397 
(313 - 502) 
> 30,000 105 
(90 - 121) 
2.02 0.26 
28 cC6H11 NHcC6H11 306 
(299 - 313) 
177 
(122 - 256) 
>  30,000 129 
(112 - 147) 
1.73 0.73 
29 cC6H11 NHCH2Ph 63.9 
(59.1 - 69.1) 
15.2 
(13.7 - 16.9) 
>  30,000 455 
(351 - 590) 
4.20 29.9 
30 CH2Ph NHCH3 2,770 
(2,560 - 3,000) 
173 
(135 - 223) 
>  30,000  275 
(260 - 291) 
16.0 1.59 
31 CH2Ph NHCH(CH3)2 > 100,000   394 
(242 - 643) 
>  30,000 114 
(108 - 121) 
> 253 0.29 
32 CH2Ph NHcC6H11 no data due to poor solubility   
33 CH2Ph NHCH2Ph 784 
(541 - 1,140) 
20.4 
(15.2 - 27.2) 
11, 800 
(6,373 - 21,932) 
37.0 
(34.2 - 40.0) 
38.4 1.81 
34 CH2-4F-Ph NHCH3 3,080 
(2,320 - 4,100) 
235 
(178 - 310) 
>  30,000  557 
(498 - 622) 
13.1 2.37 
35 CH2-4F-Ph NHcC6H11 > 100,000 112 
(92.4 - 136) 
>  30,000  1,300 
(818 - 2,050) 
> 893 11.6 
36 CH2-4F-Ph NHCH2Ph 1,490 
(1,130 - 1,980) 
21.8 
(15.5 - 30.8) 
>  30,000 75.3 
(61.3 - 92.5) 
68.3 3.45 
37 CH2-4F-Ph NHCH2-4F-Ph > 100,000  43.6 
(26.0 - 73.1) 
>  30,000 123 
(103 - 147) 
> 2,293 2.82 
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reported subseries the benzylamino substituent at the C5 position gives the best results in terms of 
affinity at the hA2A AR (i.e. 10: KihA2A = 1.11 nM; 14: KihA2A = 1.44; 18: KihA2A = 95.2 nM; 22: 
KihA2A = 5.39 nM; 29: KihA2A = 15.2; 33: KihA2A = 20.4; 36: KihA2A = 21.8). In particular, 
compound 10, bearing a free amino group at the C7 position, is the most potent compound of the 
series with a Ki value of 1.11 nM at the hA2A AR. Compared with the C7 free amino group, a 
benzamido moiety in position C7 leads to a detrimental effect (i.e. 18: KihA2A = 95.2 nM), a 
phenylacetamido moiety partially recovers the affinity (i.e. 22: KihA2A = 5.39 nM), whereas a 
phenylureido group restores the affinity (i.e. 14: KihA2A = 1.44 nM). Monoalkylamino substituents 
are also tolerated in position C7, as good affinity values are obtained with a cyclohexyl- (i.e. 29: 
KihA2A = 15.2 nM), benzyl- (i.e. 33: KihA2A = 20.4 nM) and 4-fluorobenzyl- (i.e. 36: KihA2A = 21.8 
nM) amino groups, even though the free amino group ends up being the most promising 
substitution (i.e. 10: KihA2A = 1.11 nM).  Compound 10 exhibits an 85- and 28-fold selectivity 
versus hA1 and hA3 ARs, respectively, whereas compound 14 (KihA2A = 1.11 nM) shows a 216- 
and 20.6-fold selectivity against the same receptor subtypes. In the phenylureido subseries, the 
potency decreases in the following order benzyl- > cyclohexyl- > isopropyl- > methyl-amino group 
(i.e. 14: KihA2A = 1.44 nM > 13: KihA2A = 7.87 nM > 12: KihA2A = 86.9 nM > 11: KihA2A = 99.6 
nM). 
By analyzing the binding data at the hA3 AR, it emerges that the newly synthetized derivatives do 
not show interesting affinity toward this AR subtype. As also observed for the other ARs, the best 
results in terms of affinity are obtained with a benzylamino group at C5 position (i.e. 10: KihA3 = 
30.8 nM; 14: KihA3 = 29.7nM; 22: KihA3 = 45.5 nM; 33: KihA3 = 37.0 nM; 36: KihA3 = 75.3 nM). 
The best hA3 AR antagonist obtained for the series is compound 14 (phenylureido series), which, 
further is also one of the most potent derivatives at the hA2A AR (KihA2A = 1.44 nM). 
The introduction of an isopropylamino group at C5 position generally provides a more potent hA3 
AR antagonist than the cyclohexylamino group (e.g. 12: KihA3 = 170 nM vs 13: KihA3 = 349 nM). 
In fact, in the cyclohexylamino series, the C5-isopropylamino derivative (27) is the most potent hA3 
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AR antagonist with a Ki of 105 nM with respect to the range of affinity (129-905 nM) of the other 
compounds (26, 28, 29). The introduction of a fluorine atom at the para position of the 
benzylamino group at C5 and/or C7 positions decreases the affinity at the hA3 AR (e.g.  33: KihA3 
= 37.0 nM vs 36: KihA3 = 75.3 nM vs 37: KihA3 = 123 nM) 
 In conclusion, biological data suggest that, with a few exceptions, the synthesized 
derivatives are potent hA2A AR ligands. The affinity of the compounds toward this AR subtype is 
tuned by the substitution pattern at the C5 position, whereas the selectivity profile is modulated by 
the substituent linked to the C7 position. Interestingly, the introduction of a benzylamino group at 
C5 combined with a free amino group in C7 yields affinity toward all the ARs subtypes (10: KihA1 
= 94.6 nM; KihA2A = 1.11 nM; IC50hA2B = 2,214 nM; KihA3 = 30.8 nM). The substitution of the 
free amino group at C7 with a phenylureido moiety narrows the affinity down to the hA2A and hA3 
AR subtypes (14: KihA2A = 1.44 nM; KihA3 = 29.7 nM). 
 
2.4 Molecular Modelling 
To explain from a molecular point of view the observed binding data, we carried out docking 
simulations of the new derivatives by running a previously reported computational protocol23. 
Selected compounds were docked into the orthosteric pocket of the hA2A AR X-ray structure (PDB 
code: 4EIY) and the putative TM binding site of a previously obtained hA3 AR homology model31. 
The selection of the docking poses was based upon optimal interaction geometries with the residues 
surrounding the binding site and by focusing the attention on derivatives showing Ki values falling 
into the low nanomolar range (arbitrary cut-off = 100 nM). A general analysis of the thus selected 
binding modes was performed with the aim to identify the receptor residues involved in the binding. 
The analysis was derived by computing per residue electrostatic and hydrophobic contributions to 
the interaction energy (IEele and IEhyd, respectively) and by graphically transferring the data into 
"Interaction Energy Fingerprints" (IEFs) maps. A more detailed analysis for the ligands showing 
higher activity toward the hA2A and hA3 ARs subtypes was performed through the inspection of 
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individual docking poses, as reported in the following.  
 The IEele map for the hA2A AR subtype (Figure 1A) shows five regions of negative 
potential energy with the most intense corresponding to residues located in TM2, TM6 and EL2. 
The most effective polar interaction is established with Asn253 (6.55), whereas Tyr 271 (7.36), 
His250 (6.52) and to a lesser extent Tyr9 (1.35), Glu13 (1.39), Ser 277 (7.42), and Asn181 (5.42) 
are engaged in secondary interactions.  
 
Figure 1. Per residue IEele and IEhyd maps for the most energetically favorable docking poses of 
compounds with Ki < 100 nM. The maps have been computed for selected poses of the considered 
compound inside the orthosteric binding site of hA2A  AR (panels A and B) and the putative binding 
site of hA3 AR (panels C and D). Electrostatic energy contributions are expressed in kcal/mol, 
whereas hydrophobic contributions are in arbitrary units. Ranges reported in the x-axes represent 
the length of protein sequences (truncated at 300 residues). 
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The IEhyd map (Figure 1B) displays several residues involved in hydrophobic contacts with the 
ligands, such as Phe168 (EL2) and Leu249 (6.51), Trp246 (6.48), Val84 (3.32), Ile274 (7.39), and 
Leu85 (3.33). Similar interaction patterns are also derived for the energetically more favourable 
poses of the ligands at the hA3 AR (Figure 1C and D): In particular, the most favourable 
electrostatic interactions involve Asn250 (6.55), while Tyr265 (7.36), Thr87 (3.29), and Glu19 
(1.39) establish ancillary interactions. Hydrophobic contacts include, among others, Phe168 (EL2), 
Trp243 (6.48), Leu246 (6.51), Ile268 (7.39) and Leu90 (3.32). 
 A detailed analysis of the docking poses was performed for the most active compounds at 
the hA2A and the hA3 ARs (derivatives 10 and 14). As highlighted in the SAR analysis, the 
introduction of a benzylamino group at C5 and a free amino group in C7 yields affinity toward all 
the ARs subtypes (10: KihA1 = 94.6 nM; KihA2A = 1.11 nM; IC50hA2B = 2,214 nM; KihA3 = 30.8 
nM). In Figure 2 A-D the hypothetical binding modes of compound 10 at the four ARs subtypes is 
reported.  
 
Figure 2. Hypothetical binding modes of compound 10 inside the hA1 (A), hA2A (B), hA2B (C) and 
hA3 (D) ARs binding sites. Poses are viewed from the membrane side facing TM6, TM7, and TM1, 
hydrogen bonds are highlighted as black dashed lines, and side chains of Asn (6.55), Phe (EL2), and 
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Glu (EL2) are represented as sticks. Residues interacting through hydrophobic contacts with the 
compounds are rendered as transparent surfaces. 
As can be noted, in all the poses the ligand resides in the upper region of the transmembrane (TM) 
bundle, with the TT core anchored by an aromatic π−π stacking interaction with Phe (EL2) and the 
furan ring pointing toward TM6 (see also Video S1). In particular, at the hA1, hA2A, and hA2B ARs, 
(Figure 2 A, B, and C, respectively) the scaffold is anchored in the cleft by three hydrogen bonds 
established by the free amino group at the C7 position and the N2 of the triazole ring with the 
conserved Asn (6.55) and the Glu (EL2) residues. The ligand adopts a conformation that is 
superimposable with the crystallographic binding mode of ZM 241385 at the hA2A AR (data not 
shown) with the substituent at C5 exposed toward the extracellular side and interacting with Tyr 
(7.36) at the hA1 and hA2A ARs (transparent surfaces in Figure 2A and 2C). The predicted binding 
mode at the hA3 AR (Figure 2D) envisages the scaffold shifted toward TM2 with respect to the pose 
observed at the other ARs subtypes. We ascribe this different placement to the lack of the anchoring 
hydrogen bond played by Glu (EL2) at the other ARs subtypes, residue that is replaced by a valine 
in the hA3 AR. 
 As mentioned in the SAR analysis, the introduction of a phenylureido group at C7 in place 
of a free amino group maintaining the benzylamino moiety at the C5 narrows the activity spectrum 
toward the hA2A and hA3 AR stubtypes (14: KihA2A = 1.44 nM; KihA3 = 29.7 nM). In the 
hypothetical binding mode of compound 14 at the hA2A AR (Ki = 1.44 nM, Figure 3A), the scaffold 
is flipped by about 180 degrees with respect to the predicted placement of compound 10 (Figure 
2B). The nitrogen of the benzylamino group at the C5 position establishes a hydrogen bond 
interaction with the Glu169 (EL2) sidechain, whereas the N4 of the triazole ring interacts with 
Asn253 (6.55). In this position the phenylureido group at C7 points between TM2 and TM3 and 
establishes hydrophobic contacts with Phe62 (2.60), Val84 (3.32), and Ile274 (7.39), represented as 
transparent surfaces in Figure 3A.  
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Figure 3. (A) Hypothetical binding mode of compound 14 inside the putative binding site of the 
hA2A AR. The pose is viewed from the membrane side facing TM6, TM7, and TM1, hydrogen 
bonds are highlighted as dashed black lines, and side chains of Asn253 (6.55), Phe168 (EL2), and 
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Glu169 (EL2) are represented as sticks. Residues interacting through hydrophobic contacts are 
rendered as transparent surfaces. (B) Interaction Energy Fingerprints (IEFs) for the most active 
compounds at the hA2A AR (10, 14): Electrostatic energy contributions are expressed in kcal/mol, 
whereas hydrophobic contributions are in arbitrary units. (C) Hypothetical binding mode of 
compound 14 inside the putative binding site of hA3 AR. The pose is viewed from the membrane 
side facing TM6, TM7, and TM1, hydrogen bonds are highlighted as dashed black lines, and side 
chains of Asn250 (6.55) and Phe168 (EL2) are represented as sticks. Residues interacting through 
hydrophobic contacts are rendered as transparent surfaces.  
Consistently to the above described hypothetical binding modes, the IEFs analyses for compounds 
10 and 14 at the hA2A AR (Figure 3B) identify Asn253 (6.55), Glu169 (EL2) and Phe168 (EL2) as 
the residues mainly contributing to the interaction energy, whereas different interaction patterns are 
observed for residues belonging to TM2, TM3, and TM7. These patterns, therefore, give rise to the 
different orientations of the TT scaffold, as depicted in Figure 2B and 3A. A similar trend - e.g. 
different binding modes depending on the nature of the substituents - was also previously observed 
for 5-alkylaminopyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine23 and 5,8-disubstituted-
[1,2,4]triazolo[1,5-c]pyrymidine24 derivatives. 
The hypothetical binding mode of 14 at the hA3 AR (Figure 3C) suggests that the compound 
might adopts a binding mode similar for the one observed at the hA2A AR. The main interactions 
are established with Glu19 (1.39), Asn250 (6.55) and Phe168 (EL2) and an extended pattern of 
hydrophobic interactions involves with residues located in TM2, TM3 and TM7. With respect to the 
pose in the hA2A AR, the scaffold is shifted toward TM2. Again, as also observed for compound 10, 
this shift might arise from the lack of the anchoring hydrogen bond (played by Glu169 at the hA2A 
AR, replaced by a valine residue in the hA3 AR). 
 In order to explain and capture from a molecular point of view the signatures of the activity 
of the TT scaffold at the hARs, we performed a retrospective analysis by comparing the effect of 
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the substitution at positions C5 and C7 on corresponding analogues belonging to the PTP series 
previously reported15,18. In this analysis, we focused our attention on: (a) the effect of the 
introduction of a phenylureido moiety in place of the free amino group at C7 (corresponding to 
C5PTP) position; (b) the effect of the introduction of a benzylamino substituent at C5 position, 
corresponding to the opening of the pyrazole ring of the PTP scaffold (see Chart 3). 
 
Chart 3. Structures of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines  and [1,2,4]triazolo[1,5-
a][1,3,5]triazines considered in the retrospective analysis. 
As sketched out in Chart 3, the substitution of a free amino group in C5PTP position with a 
phenylureido moiety causes a shift of the activity from the hA2A AR to the hA3 AR. In the 
hypothetical binding modes of compound A at hA2A AR (Figure 4A) the free amino group at C5PTP 
establishes a tight hydrogen bond network with Ans253 (6.55) and Glu169 (EL2), and the PTP 
scaffold is placed with the furan ring pointing toward TM6. In the hypothetical binding mode of 
compound B at the hA3 AR (Figure 4B), the PTP scaffold is turned with the furan ring pointing 
toward TM3 and the phenylureido group exposed toward the extracellular side. The only anchoring 
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hydrogen bond in the binding site is established with Ans250 (6.55) through the N7 of the pyrazole 
ring. These data are consistent with previously reported modelling studies23: the presence of polar 
(charged) residues (Glu169, His264) in the binding site of the hA2A AR does not allow ligands with 
bulky substituents (a phenylureido group in this case) to establish effective interactions. On the 
other side, these ligands are better accommodated at the hA3 AR which binding site lacks charge 
residues (Glu169 is mutated to Val169).  
 
Figure 4.  Hypothetical binding modes of previously reported compound A (A) and B (B) inside 
the orthosteric binding site of hA2A AR and the putative binding cleft of  hA3 AR, respectively. 
Poses are viewed from the membrane side facing TM6, TM7, and TM1, hydrogen bonds are 
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highlighted as black dashed lines, and side chains of receptor main residues involved in the binding 
are represented as sticks. Residues interacting through hydrophobic contacts with the compounds 
are rendered as transparent surfaces. 
The same substitution on the TT scaffold, however, does not produce the same shift of the activity 
(Chart 3). In fact, the introduction of a phenylureido group at C7 confers activity at both ARs 
subtypes. The retained affinity at the hA2A AR, in particular, can be ascribed to the presence of the 
benzylamino group at C5: the nitrogen atom of this moiety (compound 14, Figure 2C) establishes a 
hydrogen bond interaction with Glu169 (EL2) that counterbalances the disruption of the hydrogen 
bond network provided by the free amino group at C7 (compound 10, Figure 2B). Within the PTP 
series this balance of interactions is not possible due to the geometric constraints imposed by the 
pyrazole ring. 
 
3. Conclusions 
We have presented a novel series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as 
adenosine receptors antagonists. The SAR analysis has revealed that the newly synthetized 
compounds show affinity for the hA2A and hA3 ARs depending on the substitution patterns at the 
C5 and C7 positions. In particular, the substituent at C5 tunes the potency of the compounds, 
whereas the moiety linked to C7 modulates the selectivity profile. A benzylamino group at the C5 
position combined with a free amino group at the C7 position yields affinity toward all the ARs 
subtypes (compound 10: KihA1 = 94.6 nM; KihA2A = 1.11 nM; IC50hA2B = 2,214 nM; KihA3 = 30.8 
nM). The replacement of the free amino group at C7 with a phenylureido moiety yields a potent and 
quite selective hA2A AR antagonist (compound 14: hA2A AR Ki = 1.44 nM; hA1/hA2A = 216.0; 
hA3/hA2A = 20.6) and narrows the activity spectrum toward the hA2A and the hA3 AR subtypes. The 
observed trend diverges from the analyses on the pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine 
(PTP) series we have reported on in the past. With the help of an in silico receptor-driven approach, 
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we have elucidated that the key to retain activity at the hA2A AR resides in the substituent attached 
at C5: the benzylamino group interacts with the Glu169 (EL2) thus counterbalancing the loss of the 
hydrogen bond network provided by the free amino group at C7. On the other side, the static 
depiction on the final stage of the ligand recognition offered by the docking approach does not 
allow to fully explain the selectivity profile of the newly synthetized compounds thus suggesting 
that the selectivity game might be played prior the ligand reaches the orthosteric site. To this aim, a 
better depiction could be offered by methodologies that take into account the time-dependent 
evolution of the molecular system, such as classical or biased/supervised molecular dynamics 
approaches.  
 
4. Experimental Section 
4.1 Chemistry 
General. Reactions were routinely monitored by thin-layer chromatography (TLC) on silica gel 
(precoated F254 Macherey-Nagel aluminium sheets). Flash chromatography was performed using 
Macherey-Nagel 230-400 mesh silica gel or Macherey-Nagel aluminium oxide 90 neutral. Light 
petroleum ether refers to the fractions boiling at 40-60 °C. Melting points were determined on a 
Büchi-Tottoli instrument and are uncorrected. 1H-NMR were determined in CDCl3, DMSO-d6, 
acetone-d6 or CD3OD solutions with a Varian Gemini 200 spectrometer (University of Trieste), 
peaks positions are given in parts per million (δ) downfield relative to the central peak of the 
solvents, and J values are given in Hz. The following abbreviations were used: s, singlet; bs, broad 
singlet; d, doublet; dd, double doublet; bd, broad doublet; t, triplet; m, multiplet. Electrospray mass 
spectra were recorded on an ESI Bruker 4000 Esquire spectrometer, and compounds were dissolved 
in methanol. Elemental analyses indicated by the symbols of the elements were performed by the 
microanalytical laboratory of Dipartimento di Scienze Chimiche e Farmaceutiche, University of 
Trieste, and were within ± 0.4% of the theoretical values for C, H, and N.  
Synthesis of 2,4,6-triphenoxy-[1,3,5]triazine (2). A mixture of the commercial available cyanuric 
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chloride (184.4 g, 1.0 mol) was dissolved in phenol (3.0-4.0 mol) and refluxed for 5h. The hot 
reaction was extracted with methanol and a white solid was obtained. Yield quantitative; mp 235°C; 
1H-NMR (CDCl3) δ: 7.29-7.42 (m, 6H), 7.17-7.25 (m, 3H), 7.07-7.17 (m, 6H). 
Synthesis of (4,6-diphenoxy-[1,3,5]triazin-2-yl)-hydrazine (3). To a solution of compound 2 (36 g, 
0.1 mol) in dichloromethane (500 mL), hydrazine monohydrate was added (5 mL, 0.1 mol) and the 
reaction was stirred overnight. The solvent was removed and the residue suspended in isopropanol 
(300 mL) and stirred for 14 hours. Then the white solid was filtered off and 24.5 g of title 
compound were obtained (24.5 g). Yield 83%; mp 107 °C; 1H-NMR (DMSO-d6) δ: 4.34 (bs, 2H), 
7.12-7.30 (m, 6H), 7.35-7.46 (m, 4H), 9.20 (bs, 1H). 
Synthesis of furan-2-carboxylic acid N'-(4,6-diphenoxy[1,3,5]triazin-2-yl)-hydrazide (4). 
Compound 3 (24.5 g, 0.083 mol) was dissolved in dichloromethane (240 mL), triethylamine (TEA) 
(11.6 mL, 0.083 mol) was added the solution, and then a solution of 2-furoyl chloride (4.91 mL, 
0.05 mol) in dichloromethane (60 mL) was added slowly maintaining reaction at 0°C. The mixture 
was stirred for 3 hours then 2-furoyl chloride was added again (3.27 g, 0.033 mol) and the reaction 
was stirred for 12 hours at room temperature. The mixture was washed with water (2x200 mL) and 
brine (100 mL). The organic layer was dried, concentrated and purified by flash chromatography 
(EtOAc 4/ Light petroleum 6) to provide compound 4 as a white solid (16.1 g). Yield 49.8%; mp 
183 °C; 1H-NMR (CDCl3) δ: 6.7 (dd, J=1.8, J=3.4, 1H), 7.12-7.45 (m, 13H), 8.28 (bs, 1H). 
Synthesis of 2-furan-2-yl-5,7-diphenoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazine (5). The hydrazide 
derivative 4 (7.0 g, 0.018 mol) was dissolved in xylene (250 mL) and P2O5 (17 g, 0.12 mol) was 
added and the mixture was refluxed for 14 hours. The solvent was removed under reduced pressure 
and the residue was dissolved in dichloromethane (250 mL) and washed with a mixture of water 
and brine (3 x 80 mL). The organic layer was dried, concentrated and purified by flash 
chromatography (EtOAc 2/ Light Petroleum 8) to provide compound 5 as a white solid (1.4 g). 
Yield 21%; mp 246-248 °C; 1H-NMR (CDCl3) δ: 6.59 (dd, J=1.8, J=3.2, 1H), 7.11-7.51 (m, 11H), 
7.63 (s, 1H). 
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Synthesis of 2-furan-2-yl-5-phenoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine (6). To a 
solution of compound 5 (580 mg, 1.56 mmol) in methanol (40 mL) 5 mL of ammonia 7N solution 
in methanol were added, the reaction was then refluxed for 4 hours. The solvent was removed under 
reduced pressure; the residue was purified by column chromatography (EtOAc 3/ Light petroleum 7) 
and precipitated from diethyl ether and light petroleum, providing the desired compound 6 as white 
solid (423 mg). Yield 92%; white solid; mp 253 °C (EtOAc-Light petroleum); 1H-NMR (DMSO-d6) 
δ: 6.70 (dd, J=2, J=3.2, 1H), 7.12 (d, J=3.2, 1H), 7.22-7.31 (m, 3H), 7.42-7.49 (m, 2H), 7.91 (d, 
J=2, 1H), 8.99 (bd, 2H). 
General procedure for the synthesis of N5-substituted-2-furan-2-yl-[1,2,4]triazolo[1,5-
a][1,3,5]triazine-5,7-diamine (7-10). Compound 6 was dissolved in ethanol and 1.5-10 eq of the 
desired amine were added. Reaction was stirred in a sealed tube at 100°C for a time that could vary 
from 3 to 72 hours. Reaction was monitored by TLC using EtOAc 1/ Light petroleum 1 as eluent. 
The solvent was then removed and the residue was purified by column chromatography to give the 
desired compound. The solid was suspended in EtOAc, precipitated with light petroleum and 
filtered. 
2-(Furan-2-yl)-N5-methyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (7). 1g (3.40 mmol) of 
compound 6 was reacted with 2.11 mL of methylamine 33 wt. % solution in ethanol (17 mmol, 5 eq) 
for 4 hours. Eluent of column chromatography was EtOAc. White solid (300 mg, 38%); mp 244 °C; 
1H-NMR (DMSO-d6) δ: 2.79 (d, J=4.8, 3H); 6.68 (s, 1H); 7.04 (s, 1H); 7.32-7.42 (m, 1H); 7.86 (s, 
1H); 8.14 (bs, 2H). IR (Nujol) cm-1: 3284, 2884, 1657, 1586, 1514, 1496, 1407, 1369, 1316, 1227, 
910, 773. Anal. (C9H9N7O) C, H, N. 
2-Furan-2-yl-N5-isopropyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7-diamine (8). 485 mg (1.65 mmol) 
of compound 6 were reacted with 1.4 mL of isopropylamine (16.5 mmol, 10 eq) for 24 hours. 
Column chromatography with gradient elution starting at EtOAc 4/ Light petroleum 6 and ending at 
EtOAc 9/ Light petroleum 1. White solid (370 mg, 86.6%); mp 209 °C; 1H-NMR (DMSO-d6) δ: 
1.14 (d, J=6.6, 6H); 4.01-4.10 (m, 1H);  6.63 (s, 1H); 7.04 (s, 1H); 7.29 (d, J=7.8, 1H); 7.86 (s, 1H);  
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8.07 (bs, 2H). IR (Nujol) cm-1: 3418, 2876, 1659, 1608, 1572, 1514, 1362, 1324, 1182, 783, 699. 
Anal. (C11H13N7O) C, H, N. 
N5-Cyclohexyl-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7-diamine (9). 500 mg (1.70 
mmol) of compound 6 were reacted with 0.97 mL of cyclohexylamine (8.5 mmol, 5 eq) for 4 hours. 
Eluent of column chromatography was EtOAc 8/ Dichloromethane 2. White solid (195 mg, 38.3%); 
mp >250 °C; 1H-NMR (DMSO-d6) δ: 1.20-1.28 (m, 5H); 1.57-1.90 (m, 5H); 3.72 (bs, 1H); 6.67 (s, 
1H); 7.04 (s, 1H); 7.32 (d, J=8.4, 1H); 7.86 (s, 1H); 8.07 (bs, 2H). IR (Nujol) cm-1: 3440, 2919, 
2853, 1667, 1624, 1590, 1493, 1408, 1322, 1011, 765, 738. Anal. (C14H17N7O) C, H, N. In this 
reaction were obtained also 160 mg of N5,N7-dicyclohexyl-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazine-5,7-diamine (28, 24.7%). 
N5-Benzyl-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7-diamine (10). 500 mg (1.70 mmol) 
of compound 6 were reacted with 0.28 mL of benzylamine (2.55 mmol, 1.5 eq) for 72 hours. Eluent 
of column chromatography was EtOAc 8/ Dichloromethane 2. Pale yellow solid (140 mg, 26.8%); 
mp 157 °C; 1H-NMR (DMSO-d6) δ: 4.52 (s, 2H); 6.66 (s, 1H); 7.05 (s, 1H); 7.10-7.42 (m, 5H); 
7.86 (s, 1H); 7.99 (bs, 1H); 8.23 (bs, 2H). IR (Nujol) cm-1: 3418, 2072, 1655, 1650, 1632, 1588, 
1504, 1486, 1415, 1322, 770, 621. Anal. (C15H13N7O) C, H, N. 
General procedure for the synthesis of 1-(2-(furan-2-yl)-5-(substitutedamino)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-yl)-3-phenylurea (11-14). The appropriate N5-substituted-2-furan-2-yl-
[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (7-10, 0.3 mmol) was dissolved in 5 mL of dry 1,4-
dioxane and 0.45 mmol of phenylisocyanate (49 µL, 1.5 eq) were added. The solution was stirred at 
reflux for 24h. The reaction was monitored by TLC (EtOAc 3/ light petroleum 7 or EtOAc 4/ Light 
petroleum 6). The solvent was then removed and the residue was purified by column 
chromatography (EtOAc 3/ Light petroleum 7) to give the desired compound (11-14). The solid was 
suspended in EtOAc, precipitated with light petroleum and filtered. 
1-(2-(Furan-2-yl)-5-(methylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-3-phenylurea (11). 
White solid (15.8 mg, 15%); mp 194 °C; 1H-NMR (DMSO-d6) δ: 2.89 (d, J=4.4, 3H); 6.71 (s, 1H); 
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7.13-7.19 (m, 2H); 7.37 (t, J=7.6, 2H); 7.66 (d, J=7.6, 2H); 7.93 (s, 1H); 8.26 (bs, 1H); 10.24 (bs, 
1H); 10.57 (s, 1H). IR (Nujol) cm-1: 3044, 1718, 1633, 1614, 1538, 1513, 1486, 1407, 1396, 1308, 
1241, 1185, 1107, 1011, 967, 773, 749, 700, 688, 627. Anal. (C16H14N8O2) C, H, N. 
1-(2-(Furan-2-yl)-5-(isopropylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-3-phenylurea (12). 
Pale yellow solid (9 mg, 8%); mp 173°C; 1H-NMR (DMSO-d6) δ: 1.22 (s, 6H); 4.11 (bs, 1H); 6.71 
(s, 1H); 7.13 (s, 2H); 7.38 (s, 2H); 7.63 (s, 2H); 7.92 (s, 1H); 8.18 (bs, 1H); 10.26 (bs, 1H); 10.46 (s, 
1H). IR (Nujol) cm-1: 3403, 1647, 1527, 1512, 1447, 1430, 1308, 1237, 1182, 1131, 1080, 1012, 
968, 686. Anal. (C18H18N8O2) C, H, N. 
1-(5-Cyclohexylamino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-3-phenylurea (13). 
White solid (15 mg, 12%); mp 216 °C; 1H-NMR (DMSO-d6) δ: 1.14-1.31 (m, 5H); 1.61-1.98 (m, 
5H); 3.77 (bs, 1H); 6.71 (s, 1H); 7.12 (bs, 2H); 7.37 (t, J=7.6, 2H); 7.64 (d, J=7.6, 2H); 7.92 (s, 1H); 
8.16 (bs, 1H); 10.30 (bs, 1H); 10.43 (s, 1H). IR (Nujol) cm-1: 3418, 2938, 2854, 1707, 1645, 1593, 
1530, 1511, 1446,   1409, 1310, 1230, 1181, 1131, 1013, 968, 904, 884, 776, 746, 690. Anal. 
(C21H22N8O2) C, H, N. 
1-(5-Benzylamino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-3-phenylurea (14). Pale 
yellow solid (29 mg, 23%); mp 142 °C; 1H-NMR (DMSO-d6) δ: 4.59 (d, J=5, 2H); 6.71 (s, 1H); 
7.12 (bs, 2H); 7.21-7.53 (m, 7H); 7.66 (d, J=7.7, 2H); 7.93 (s, 1H); 8.85 (bs, 1H);10.28 (bs, 1H); 
10.58 (s, 1H). IR (Nujol) cm-1: 3369, 1700, 1640, 1532, 1508, 1449, 1364, 1353, 1311, 1238, 1182, 
1133, 1012, 970, 904, 777, 744, 700, 692. Anal. (C22H18N8O2) C, H, N. 
General procedure for the synthesis of N-(2-(furan-2-yl)-5-(substitutedamino)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-yl)benzamide (15-18) and N-(2-(furan-2-yl)-5-(substitutedamino)-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-2-phenylacetamide (19-22). 0.3 mmol of N5-substituted-2-
furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (7-10) were dissolved in 5 mL of 1,4-
dioxane, then 0.36 mmol of benzoylchloride (46 mg, 42 µL, for compounds 15-18) or 
phenylacetylchloride (56 mg, 48 µL, for compounds 19-22) and 0.36 mmol (36 mg, 50 µL) of TEA 
were added to the solution. Reaction was stirred under reflux for 24 h and then it was monitored by 
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TLC (EtOAc 3/ Light petroleum 7 or EtOAc 4/ Light petroleum 6). Reactions do not go to 
completion. The solvent was removed under reduced pressure; the residue was dissolved in 
dichloromethane and washed three times with water and brine. Organic layers were collected, dried 
on sodium sulfate anhydrous and the solvent was removed. The crude was purified by column 
chromatography (EtOAc/ Light petroleum mixtures) to give the desired compounds 15-22 that were 
further suspended in EtOAc and precipitated with light petroleum.  
N-(2-(Furan-2-yl)-5-(methylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)benzamide (15). 
Column chromatography with gradient elution starting at EtOAc 3/ Light petroleum 7. White solid 
(23 mg, 23%); mp 233 °C; 1H-NMR (DMSO-d6) δ: 3.49 (s, 3H); 6.69 (s, 1H); 7.13 (s, 1H); 7.34-
7.48 (m, 5H); 7.90 (s, 1H); 8.80 (bs, 1H); 8.89 (bs, 1H). IR (Nujol) cm-1: 3397, 1689, 1644, 1604, 
1573, 1506, 1430, 1418, 1372, 1341, 1318, 1241, 1220, 1180, 1119, 1040, 1013, 782, 730, 698. 
Anal. (C16H13N7O2) C, H, N. 
N-(2-(Furan-2-yl)-5-(isopropylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)benzamide (16). 
Column chromatography with gradient elution starting at EtOAc 3/ Light petroleum 7. Pale yellow 
solid (33.8 mg, 31%); mp 110 °C; 1H-NMR (DMSO-d6) δ:  1.42 (d, J=5.6, 6H); 4.74-5.25 (m, 1H); 
6.69 (s, 1H); 7.12 (s, 1H); 7.23-7.71 (m, 5H); 7.90 (s, 1H); 8.75 (bs, 1H); 8.83 (bs, 1H). IR (Nujol) 
cm-1: 3424, 2988, 2927, 1654, 1560, 1512, 1448, 1404, 1270, 1178, 1126, 1078, 1015, 974, 781. 
Anal. (C18H17N7O2) C, H, N. 
N-(5-(Cyclohexylamino)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)benzamide (17). 
Column chromatography with gradient elution starting at EtOAc 2/ Light petroleum 8. White solid 
(33.9 mg, 28%); mp 220 °C; 1H-NMR (DMSO-d6) δ:  
1.17-1.36 (m, 3H); 1.62-2.04 (m, 7H); 4.59 (bs, 1H); 6.69 (s, 1H); 7.13 (s, 1H); 7.33-7.50 (m, 5H); 
7.90 (s, 1H); 8.77 (bs, 1H); 8.87 (bs, 1H). IR (Nujol) cm-1: 3422, 2929, 2856, 1657, 1599, 1555, 
1511, 1450, 1409, 1324, 1276, 1263, 1248, 1178, 1127, 1012, 906, 782, 733, 697. MS-ESI (MeOH): 
m/z = 404.3 (M+1); 426.3 (M+23); 442.4 (M+39). Anal. (C21H21N7O2) C, H, N. 
N-(5-(Benzylamino)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)benzamide (18). 
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Column chromatography with gradient elution starting at EtOAc 2/ Light petroleum 8. White solid 
(32 mg, 26%); mp 200 °C; 1H-NMR (DMSO-d6) δ: 5.26 (s, 2H); 6.69 (s, 1H); 7.12 (s, 1H); 7.17-
7.71 (m, 10H); 7.90 (s, 1H); 8.82 (bs, 1H); 8.90 (bs, 1H). IR (Nujol) cm-1: 3422, 1660, 1625, 1599, 
1556, 1512, 1453, 1404, 1366, 1324, 1292, 1253, 1178, 1128, 1075, 1014, 970, 907, 782, 727, 699. 
Anal. (C22H17N7O2) C, H, N. 
N-(2-(Furan-2-yl)-5-(methylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-2-phenylacetamide 
(19). 72h of reaction. Column chromatography with gradient elution starting at EtOAc 2/ Light 
petroleum 8. White solid (20 mg, 19%); mp> 250 °C; 1H-NMR (DMSO-d6) δ: 2.83 (s, 3H); 4.05 (s, 
2H); 6.70 (s, 1H); 7.14 (s, 1H); 7.33 (s, 5H); 7.92 (s, 1H); 8.07 (bs, 1H); 11.22 (bs, 1H). IR (Nujol) 
cm-1: 3431, 1654, 1636, 1618, 1542, 1508, 1459, 1404, 1342, 1303, 1270, 1214, 1178, 1110, 1008, 
972, 903, 882, 776, 701, 686. Anal. (C17H15N7O2) C, H, N. 
N-(2-(Furan-2-yl)-5-(isopropylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-2-phenylacetamide 
(20). Column chromatography with gradient elution starting at EtOAc 4/ Light petroleum 6. White 
solid (31 mg, 27%); mp 189 °C; 1H-NMR (DMSO-d6) δ: 1.17 (d, J=6.3, 6H); 3.90-4.31 (m, 3H); 
6.71 (s, 1H); 7.13 (s, 1H); 7.19-7.41 (m, 5H); 7.92 (s, 1H); 8.02 (d, J=7.8, 1H); 11.27 (bs, 1H). IR 
(Nujol) cm-1: 3404, 2973, 2933, 1736, 1646, 1619, 1588, 1542, 1522, 1432, 1413, 1388, 1366, 1341, 
1314, 1265, 1224, 1178, 1136, 1104, 1076, 1031, 1014, 975, 905, 884, 861, 780, 734, 700. Anal. 
(C19H19N7O2) C, H, N. 
N-(5-(Cyclohexylamino)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-2-
phenylacetamide (21). Column chromatography with gradient elution starting at EtOAc 3/ Light 
petroleum 7. Yellow solid (42 mg, 34%); mp 200 °C; 1H-NMR (DMSO-d6) δ: 1.13-1.28 (m, 5H); 
1.57-1.88 (m, 5H); 3.74 (bs, 1H); 4.05 (bs, 2H); 6.71 (s, 1H); 7.13 (s, 1H); 7.33 (bs, 5H); 7.92 (s, 
1H); 8.06 (d, J=7.4, 1H); 11.20 (bs, 1H). IR (Nujol) cm-1: 3392, 2927, 2909, 1740, 1646, 1618, 
1590, 1560, 1540, 1522, 1496, 1458, 1406, 1360, 1307, 1262, 1226, 1178, 1163, 1144, 1106, 1050, 
1010, 968, 826, 779, 754, 742, 704, 680, 664. Anal. (C22H23N7O2) C, H, N. 
N-(5-(Benzylamino)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)-2-phenylacetamide 
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(22). Column chromatography with gradient elution starting at EtOAc 3/ Light petroleum 7. Yellow 
solid (25.5 mg, 20%); mp 145 °C; 1H-NMR (acetone-d6) δ: 4.31 (s, 2H); 4.73 (t, J=7.2, 2H); 6.65 
(m, 1H); 7.12 (d, J=3.2, 1H); 7.21-7.65 (m, 10H); 7.79 (s, 1H); 7.87 (bs, 1H); 9.75 (bs, 1H). IR 
(Nujol) cm-1: 3420, 2355, 1734, 1644, 1620, 1539, 1520, 1496, 1454, 1420, 1388, 1360, 1314, 1267, 
1220, 1159, 1134, 1106, 1098, 1075, 1028, 1013, 973, 905, 884, 779, 742, 700. Anal. (C23H19N7O2) 
C, H, N. 
General procedure for the synthesis of N-alkyl-2-(furan-2-yl)-5-phenoxy-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amine (23-25) and N5,N7-di(4-fluorobenzyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5,7-diamine (37). 500 mg of compound 5 (1.348 mmol) were dissolved in 10 mL of 
ethanol. 1.348 mmol  of the desired amine were added to the solution and the reaction was stirred at 
60°C for 3 hours. The reaction was monitored by TLC (EtOAc 3/ Light petroleum 7). When the 
starting material was disappeared, the solvent was removed and the crude purified by column 
chromatography with gradient elution starting at EtOAc 2/ Light petroleum 8. 
N-Cyclohexyl-2-(furan-2-yl)-5-phenoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (23). White 
solid (264 mg, 52%); mp 178 °C; 1H-NMR (DMSO-d6) δ: 0.94-1.41 (m, 3H); 1.41-1.95 (m, 7H); 
3.86 (bs, 1H); 6.69 (dd, J=3.2, J=1.8, 1H); 7.12 (d, J=3.2, 1H); 7.19-7.38 (m, 3H); 7.46 (t, J=7.6, 
2H); 7.91 (s, 1H); 9.25 (bs, 1H). IR (Nujol) cm-1: 3388, 2930, 2856, 2362, 2057, 1640, 1603, 1560, 
1522, 1511, 1490, 1451, 1418, 1385, 1321, 1294, 1228, 1186, 1128, 1073, 1060, 1012, 974, 906, 
885, 779, 754, 740, 690, 650. Anal. (C20H20N6O2) C, H, N. 
N-Benzyl-2-(furan-2-yl)-5-phenoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (24). White solid 
(170 mg, 33%); mp 190 °C; 1H-NMR (CDCl3) δ: 4.78 (d, J=5.8, 2H); 6.55 (dd, J=3.4, J=1.8, 1H); 
6.86 (bs, 1H); 7.05-7.53 (m, 10H); 7.56 (s, 1H). IR (Nujol) cm-1: 3470, 1636, 1618, 1604, 1570, 
1559, 1540, 1522, 1490, 1456, 1414, 1388, 1362, 1306, 1229, 1177, 1131, 1065, 1022, 968, 907, 
834, 778, 754, 704, 680, 663, 650, 634, 622. Anal. (C21H16N6O2) C, H, N. 
N-(4-Fluorobenzyl)-2-(furan-2-yl)-5-phenoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (25). 
From 1.26 g of compound 5 (3.39 mmol) and 388 µL of 4-fluorobenzylamine (425 mg, 3.39 mmol). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
29 
 
White solid (140 mg, 10%); mp 201 °C; 1H-NMR (DMSO-d6) δ: 4.53 (s, 2H); 6.70 (s, 1H); 6.88-
7.36 (m, 8H); 7.36-7.68 (m, 2H); 7.92 (s, 1H); 9.91 (bs, 1H). IR (Nujol) cm-1: 3392, 1643, 1604, 
1587, 1510, 1489, 1416, 1224, 778, 750. Anal. (C21H15FN6O2) C, H, N. Further elution of the 
column with EtOAc 9/light petroleum 1 gave N5,N7-di(4-fluorobenzyl)-2-(furan-2-yl)-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7-diamine (37). White solid (120 mg, 16%); mp 193 °C; 1H-
NMR (DMSO-d6) δ: 4.47 (d, J=5.3, 2H); 4.58 (d, J=6.8, 2H); 6.66 (dd, J=3.4, J=1.8, 1H); 6.84-
7.22 (m, 4H); 7.22-7.61 (m, 4H); 7.86 (s, 1H); 8.14 (bs, 1H); 9.18 (bs, 1H). IR (Nujol) cm-1: 3449, 
1633, 1613, 1556, 1563, 1494, 1412, 1306, 1222, 778, 737. Anal. (C22H18FN7O) C, H, N.  
Procedure for the synthesis of N5,N7-dicyclohexyl-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5,7-diamine (28). 500 mg of compound 5 (1.348 mmol) were dissolved in 10 mL of 
ethanol. 0.46 mL of cyclohexylamine (401 mg, 4.043 mmol) were added to the solution and the 
reaction was stirred at reflux for 3 hours. The reaction was monitored by TLC (EtOAc 3/ light 
petroleum 7). When the starting material was disappeared, the solvent was removed and the crude 
purified by column chromatography with gradient elution starting at EtOAc 2/ Light petroleum 8 to 
provide 95 mg of compound 23 (18.7%) and 53 mg of the desired compound 28 (white solid, 10%). 
Compound 28: mp 205 °C. 1H-NMR (CDCl3) δ: 1.02-1.55 (m, 10H); 1.55-1.95 (m, 6H); 1.95-2.27 
(m, 4H); 3.95 (bs, 1H); 5.14 (d, J=8, 1H); 6.02 (d, J=8.1, 1H); 6.54 (dd, J=1.7, J=3.3, 1H); 7.18 (d, 
J=3.3, 1H); 7.56 (s, 1H). IR (Nujol) cm-1: 3402, 2925, 2850, 1641, 1597, 1559, 1488, 1432, 1181, 
779, 737. Anal. (C20H27N7O) C, H, N. 
Procedure for the synthesis of N5,N7-dibenzxyl-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5,7-diamine (33). 50 mg of compound 5 (0.135 mmol) were dissolved in 2 mL of ethanol. 74 µL of 
benzylamine (72 mg, 0.674 mmol) were added to the solution and the reaction was stirred at 120 °C 
in a sealed tube for 3 hours. The reaction was monitored by TLC (EtOAc 1/ Light petroleum 1). 
When the starting material was disappeared, the solvent was removed and the crude purified by 
column chromatography with gradient elution starting at EtOAc 1/ Light petroleum 1 to provide 37 
mg of the desired compound 33 (white solid, 70%). Mp 148 °C. 1H-NMR (DMSO-d6) δ: 4.48-4.62 
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(m, 4H); 6.67 (s, 1H); 7.06 (s, 1H); 7.13-7.59 (m, 10H); 7.87 (s, 1H); 8.16 (bs, 1H); 9.14 (bs, 1H). 
IR (Nujol) cm-1: 3414, 1644, 1496, 1421, 1306, 1182, 778, 735, 697. Anal. (C22H19N7O) C, H, N. 
General procedure for the synthesis of N5,N7-disubstituted-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5,7-diamine (26,27,29-32,34-36). 45-73 mg of compounds 23-25 were dissolved in 
2-4 mL of ethanol. 1.1-4.5 eq of the desired amine were added to the solution and the reaction was 
stirred at 70-100°C from 24 to 72 hours. The solvent was then removed, and the crude was purified 
by column chromatography (EtOAc/ Light petroleum mixtures). The obtained solid was dissolved 
in EtOAc and precipitated with light petroleum providing the desired compound as a solid 
(26,27,29-32,34-36).  
N7-Cyclohexyl-2-(furan-2-yl)-N5-methyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (26). 50 
mg of compound 23 (0.133 mmol) were reacted with 66 µL of methylamine 33 wt. % solution in 
ethanol (50 mg, 0.532 mmol) at 70 °C for 72 hours.  Column chromatography with gradient elution 
starting at EtOAc 6/ Light petroleum 4. Pale yellow solid (26 mg, 63%); mp 114 °C; 1H-NMR 
(DMSO-d6) δ: 0.96-1.40 (m, 3H); 1.40-1.69 (m, 3H); 1.80 (t, J=12,3, 4H); 2.79 (d, J=4, 3H); 3.94 
(bs, 1H); 6.67 (s, 1H); 7.05 (s, 1H); 7.49 (d, J=4, 1H); 7.87 (s, 1H); 8.31 (d, J=8.3, 1H). IR (Nujol) 
cm-1: 3378, 2937, 2850, 1643, 1600, 1566, 1504, 1412, 1180, 779, 739. Anal. (C15H19N7O) C, H, N. 
N7-Cyclohexyl-2-(furan-2-yl)-N5-isopropyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (27). 
70 mg of compound 23 (0.186 mmol) were reacted with 48 µL of isopropylamine (33 mg, 0.558 
mmol) at 70 °C for 24 hours.  Column chromatography with gradient elution starting at EtOAc 0.4/ 
Dichloromethane 9.6. White solid (26 mg, 55%); mp 134 °C; 1H-NMR (CD3OD) δ: 1.27 (d, J=6.5, 
6H); 1.34-1.59 (m, 4H); 1.59-1.94 (m, 4H); 2.03 (bs, 2H); 4.02 (bs, 1H); 4.12-4.22 (m, 1H); 6.61 
(dd, J=1.8, J=3.4, 1H); 7.11 (d, J=3.4, 1H); 7.69 (d, J = 0.8 Hz, 1H). IR (Nujol) cm-1: 3394, 2930, 
2849, 1642, 1600, 1562, 1489, 1414, 1180, 780, 737. Anal. (C17H23N7O) C, H, N. 
N5-Benzyl-N7-cyclohexyl-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (29). 73 
mg of compound 23 (0.194 mmol) were reacted with 23 µL of benzylamine (23 mg, 0.213 mmol) at 
70 °C for 72 hours.  Column chromatography with gradient elution starting at EtOAc 3/ Light 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
31 
 
petroleum 7. White solid (50 mg, 67%); mp 231 °C; 1H-NMR (DMSO-d6) δ: 0.88-1.94 (m, 10H); 
3.94 (bs, 1H); 4.48 (d, J=5.8, 2H); 6.67 (bs, 1H); 7.04 (d, J=3.2, 1H); 7.11-7.57 (m, 5H); 7.86 (s, 
1H); 7.99-8.30 (m, 1H); 8.41 (d, J=8.3, 1H). IR (Nujol) cm-1: 3402, 2923, 2848, 1635, 1614, 1574, 
1494, 1421, 1318, 1182, 779, 731, 708, 695. Anal. (C21H23N7O) C, H, N. 
N7-Benzyl-2-(furan-2-yl)-N5-methyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (30). 50 mg 
of compound 24 (0.130 mmol) were reacted with 48 µL of methylamine 33 wt. % solution in 
ethanol (37 mg, 0.390 mmol) at 80 °C for 24 hours.  Column chromatography with gradient elution 
starting at EtOAc 3/ light petroleum 7. White solid (27 mg, 65%); mp 193 °C; 1H-NMR (DMSO-d6) 
δ: 2.80 (s, 3H); 4.62 (s, 2H); 6.68 (s, 1H); 7.06 (s, 1H); 7.15-7.71 (m, 6H); 7.87 (s, 1H); 9.11 (s, 1H). 
IR (Nujol) cm-1:3450, 1644, 1611, 1570, 1500, 1413, 778, 737, 696. Anal. (C16H15N7O) C, H, N. 
N7-Benzyl-2-(furan-2-yl)-N5-isopropyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (31). 98 
mg of compound 24 (0.254 mmol) were reacted with 66 µL of isopropylamine (45 mg, 0.762 mmol) 
at 70 °C for 24 hours.  Column chromatography in aluminum oxide grade III with gradient elution 
starting at EtOAc 4/ Light petroleum 6. White solid (37 mg, 42%); mp 191 °C; 1H-NMR (DMSO-d6) 
δ: 1.13 (d, J=5.4, 6H); 3.79-4.27 (m, 1H); 4.62 (s, 2H); 6.67 (s, 1H); 7.06 (s, 1H); 7.17-7.71 (m, 
6H); 7.87 (s, 1H); 9.10 (bs, 1H). IR (Nujol) cm-1: 3402, 2970, 2923, 1643, 1602, 1566, 1493, 1432, 
1317, 1180, 780, 738, 697.  Anal. (C18H19N7O) C, H, N. 
N7-Benzyl-N5-cyclohexyl-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (32). 50 
mg of compound 24 (0.130 mmol) were reacted with 45 µL of cyclohexylamine (39 mg, 0.390 
mmol) at 70 °C for 24 hours.  Column chromatography with gradient elution starting at EtOAc 3/ 
Light petroleum 7. White solid (25 mg, 53%); mp 122 °C; 1H-NMR (DMSO-d6) δ: 0.84-1.41 (m, 
5H); 1.57-1.88 (m, 5H); 3.69 (bs, 1H); 4.60 (d, J=9.6, 2H); 6.68 (s, 1H); 7.05 (s, 1H); 7.23-7.53 (m, 
6H); 7.87 (s, 1H); 9.07 (bs, 1H). IR (Nujol) cm-1: 3432, 2925, 2848, 1644, 1488, 1431, 1316, 1180, 
778, 736. Anal. (C21H23N7O) C, H, N. 
N7-(4-Fluorobenzyl)-2-(furan-2-yl)-N5-methyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 
(34). 45 mg of compound 25 (0.112 mmol) were reacted with 63 µL of methylamine 33 wt. % 
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solution in ethanol (47 mg, 0.504 mmol) at 90 °C for 48 hours.  Column chromatography with 
gradient elution starting at EtOAc 3/ Light petroleum 7. White solid (25 mg, 66%); mp 126 °C; 1H-
NMR (DMSO-d6) δ: 2.80 (d, J=4.1, 3H); 4.59 (s, 2H); 6.67 (s, 1H); 7.04-7.19 (m, 3H); 7.41-7.48 
(m, 3H); 7.86 (s, 1H); 9.08 (bs, 1H). IR (Nujol) cm-1: 3444, 1653, 1644, 1507, 1456, 1412, 1218, 
1124, 1009, 735. Anal. (C16H14FN7O) C, H, N. 
N5-Cyclohexyl-N7-(4-fluorobenzyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-
diamine (35). 45 mg of compound 25 (0.112 mmol) were reacted with 35 µL of cyclohexylamine 
(28 mg, 0.280 mmol) at 100 °C for 48 hours.  Column chromatography with gradient elution 
starting at EtOAc 3/ Light petroleum 7. White solid (30 mg, 67%); mp 127 °C; 1H-NMR (DMSO-d6) 
δ: 0.92-1.48 (m, 5H); 1.50-2.13 (m, 5H); 3.70 (bs, 1H); 4.59 (s, 2H); 6.67 (s, 1H); 6.90-7.19 (m, 
3H); 7.33-7.74 (m, 3H); 7.86 (s, 1H); 9.04 (s, 1H). IR (Nujol) cm-1: 3429, 2926, 2850, 1642, 1608, 
1570, 1509, 1488, 1415, 1314, 1220, 1181, 779, 739. Anal. (C21H22FN7O) C, H, N. 
N5-Benzyl-N7-(4-fluorobenzyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 
(36). 45 mg of compound 25 (0.112 mmol) were reacted with 30 µL of benzylamine (30 mg, 0.280 
mmol) at 100 °C for 48 hours.  Column chromatography with gradient elution starting at EtOAc 3/ 
Light petroleum 7. White solid (19 mg, 41%); mp 174 °C; 1H-NMR (DMSO-d6) δ: 4.28-480 (m, 
4H); 6.67 (s, 1H); 6.85-7.68 (m, 10H); 8.86 (s, 1H); 8.14 (bs, 1H); 9.18 (bs, 1H). IR (Nujol) cm-1: 
3424, 1644, 1623, 1612, 1570, 1507, 1497, 1420, 1306, 1221, 1182, 779, 736, 697. Anal. 
(C22H18FN7O) C, H, N. 
4.2 Biological activity.  
Binding at human A1, A2A and A3 ARs. All pharmacological methods followed the procedures as 
described earlier32. In brief, membranes for radioligand binding were prepared from CHO cells 
stably transfected with hAR subtypes in a two-step procedure. In a first step cell fragments and 
nuclei were removed at 1,000 x g and then the crude membrane fraction was sedimented from the 
supernatant at 100,000 x g. The membrane pellet was resuspended in the buffer used for the 
respective binding experiments, frozen in liquid nitrogen and stored at 80 °C. For radioligand 
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binding at the hA1 AR 1 nM [3H]CCPA was used, whereas 10 nM [3H]NECA was used for h A2A 
and 1 nM [3H]HEMADO was used for hA3 AR binding. Non specific binding of [3H]CCPA 
was determined in the presence of 1 mM theophylline, in the case of [3H]NECA and 
[3H]HEMADO 100 µM R-PIA was used33. Ki values from competition experiments were 
calculated with the program SCTFIT. 
Adenylyl cyclase activity. The potency of antagonists at the hA2B AR was determined in adenylyl 
cyclase experiments. The procedure was carried out as described previously with minor 
modifications32,34. Membranes were prepared from CHO cells stably transfected with hA2B ARs by 
only one high speed centrifugation of the homogenate. The resulting crude membrane pellet was 
resuspended in 50 mM Tris/HCl, pH 7.4 and immediately used for the cyclase assay. Membranes 
were incubated with about 150,000 cpm of [α-32P]ATP for 20 min in the incubation mixture as 
described without EDTA and NaCl34,35. The IC50-values for concentration-dependent inhibition of 
NECA-stimulated adenylyl cyclase caused by antagonists were calculated with the Hill equation. 
Hill coefficients in all experiments were near unity.  
 
4.3 Molecular Modelling 
Energy computation and analyses of docking poses were performed using the MOE36 suite 
(Molecular Operating Environment, version 2014.09). Docking simulations were carried out with 
the GOLD37 (Genetic Optimization for Ligand Docking, version 5.2) suite. 
Three-Dimensional Structures of hARs. Among all the currently available crystallographic 
structures of hA2A AR, we selected for our docking simulations a complex with the selective and 
high affinity inverse agonist ZM 241385. Among the structures co-crystallized with ZM 241385, 
we selected the one with the highest resolution and fewest missing atoms (PDB code: 4EIY, 1.80 Å 
resolution)38. As, to date, no crystallographic information about all other AR subtypes are available, 
we used a previously build homology models deposited in our web platform dedicated to ARs, 
Adenosiland39,40. The numbering of the amino acids follows the arbitrary scheme proposed by 
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Ballesteros and Weinstein41: each amino acid identifier starts with the helix number (1–7), followed 
by a dot and the position relative to a reference residue among the most conserved amino acids in 
that helix, to which the number 50 is arbitrarily assigned. 
Molecular Docking. Ligand structures were built using the MOE-builder tool, as part of the MOE 
suite36, and were subjected to a MMFF94x energy minimization until the rms conjugate gradient 
was <0.05 kcal mol –1 Å –1. We used the Protonate 3D42 methodology, part of the MOE suite, for 
protonation state assignments. According to the docking benchmark study we have previously 
conducted43, docking simulations were performed with the docking tool of GOLD37 suite as 
conformational search program and the GoldScore as scoring function. For each selected 
compound, 20 independent docking runs were performed and searching was conducted within a 
user-specified docking sphere (20 Å radius and centered on the barycenter of the Asn(6.55) 
residue). Electrostatic and hydrophobic contributions to the binding energy of individual receptor 
residues have been calculated using the MOE36 suite (see below). To estimate the electrostatic 
contributions, atomic partial charges for the ligands were calculated using PM3/ESP methodology. 
Partial charges for protein amino acids were calculated with the AMBER99 force field. 
Interaction Energy Fingerprints (IEFs). Individual electrostatic and hydrophobic contributions to 
the interaction energy (hereby denoted as IEele and IEhyd, respectively) of each receptor residue 
involved in the binding with the ligand were computed with the MOE36 suite . In particular, the 
IEele was computed on the basis of the nonbonded electrostatic interaction energy term of the force 
field, whereas the IEhyd contributions was calculated by using the directional hydrophobic 
interaction term based on contact surfaces as implemented in the MOE36 scoring function. IEele 
values are expressed in kcal/mol, whereas IEhyd values are reported as adimensional scores (the 
higher the better). The IEFs analysis are graphically transferred either into colored maps or into 
histograms reporting the key residues involved in the binding with the considered ligands along 
with a quantitative estimate of the occurring interactions. 
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• A series of triazolo-triazines was developed as adenosine receptor (AR) antagonists 
• Compounds show better affinity at the hA2A and hA3 ARs than at the hA1 and hA2B ARs 
• A benzylamino group at the C5 position gives highest affinity values at the hARs 
• Docking simulations were carried out to explain the observed binding data 
